Physician profile
Brian Gwartz
NPI 1619095247
$1,208.56
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,209.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $280.52 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $218.39 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.13 | 2019 | |
| Scilex Pharmaceuticals INC. | $118.27 | 2019 | |
| Vertiflex, INC. | $115.73 | 2019 | |
| Medtronic USA, INC. | $52.75 | 2019 | |
| Pfizer INC. | $36.73 | 2019 | |
| Kaleo, INC. | $35.69 | 2019 | |
| West Therapeutics Development, LLC | $31.48 | 2019 | |
| Collegium Pharmaceutical, INC. | $27.61 | 2019 | |
| Shionogi INC | $24.89 | 2019 | |
| Sentynl Therapeutics, INC. | $24.83 | 2019 | |
| Avanos Medical | $21.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.04 | 2019 | |
| Zyla Life Sciences, INC. | $17.43 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.